April 6, 2017 / 5:25 AM / 6 months ago

BRIEF-Novartis to in-license ECF843 for ophthalmic indications

April 6 (Reuters) - Novartis Ag

* Novartis to strengthen research and development pipeline by in-licensing ECF843 for ophthalmic indications

* Says exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe) Source text for Eikon: [here ] Further company coverage: (Reporting By Zurich newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below